Key Takeaways
- FY24 hit by severe export destocking: Revenue fell 23% YoY to ₹696 crores, with exports down 44%, as global channel inventory overhang and adverse weather crushed volumes.
- Q4 was a one-off trough: Revenue plunged 37% YoY to ₹127 crores, worsened by a sudden order halt for one legacy export product; management frames this as the bottom.
- Recovery bet is volume-led, not price-led: Prices have stopped declining but are rising very slowly; the 15-20% FY25 growth target hinges entirely on volume recovery from new products and destocking ending.
- Margin visibility is poor, guidance withdrawn: Earlier 20-22% EBITDA margin guidance was explicitly dropped; management needs 1-2 more quarters before it can commit to a number.
- What to watch next quarter: Whether Q1 FY25 actually delivers the promised ₹201+ crores revenue (20% QoQ jump), the pace of export order normalization, and any concrete margin guidance.
The Export Destocking Shock
- Export collapse drove the year: Export turnover fell 44% in FY24 and 65% in Q4, with Europe and Australia hit by both adverse weather and high channel inventory.
- Legacy product order halt blindsided Q4: One old legacy product from the export market received no orders from mid-February through March, causing export turnover to decline more than management had expected just weeks earlier.
- Volume decline concentrated in legacy: Volume decline in legacy products like Prosulfocarb, Captan and Folpet was much steeper than in new products.
- Industry-wide, not company-specific: Management stressed the entire agrochemical industry globally faces the same demand resistance across both old and new products.
- Destocking is easing: Channel inventory has declined, which has started to bring up demand; management expects the process to slowly complete.
Gupta: "Actually, February mid and March month, we did not receive any order of our one of the old legacy products from export market. So, the export turnover has declined more than what we were expecting."
Margin Compression & Cost Structure
- EBITDA margin halved: Fell to 15% in FY24 from 24% in FY23, driven by sluggish global demand and lower product price realization; PAT margin settled at 9%.
- Q4 margin distorted by job work shift: Other expenses spiked because the company converted two raw materials to a job work basis, paying ₹6 crores in job work charges that inflated other expenses and reduced cost of materials. This arrangement will continue from Q2 onwards, with Q1 job work charges likely very low.
- Raw material stability, but no pricing power: Raw material costs have become stable and prices have stopped declining, but prices are rising very slowly, keeping margins at reduced levels.
- New products may help, but unproven: Management's calculation suggests new products carry higher margins than the current basket, but it refused to commit, citing how fast the scenario changes.
Jain: "By making the decision, by making the calculation we feel so but the scenario changes very fast nowadays. So that is why we are not able to exactly commit to you what margin we would have."
Recovery Thesis: Volume Over Price
- Growth target is 15-20% for FY25 and FY26: Driven by new products, better demand for old products, good export orders, and volume recovery.
- Volume recovery leads, pricing lags: More recovery is expected to be volume-driven than price-driven; prices are rising only very slowly.
- FY23 volume not crossed in FY25: Management expects to reach near FY23 volume levels in FY25 but not cross them; FY26 should definitely exceed FY23 revenue on compounded 15-20% growth.
- Q1 FY25 quantified: Revenue expected around ₹201 crores, at least 20% above Q4 FY24, and better than Q1 of last year; growth driven primarily by exports and demand for old legacy products.
- Demand stabilization timeline: Management expects another 1-2 quarters before stabilization; the coming two quarters should improve.
Strategic Build-Out: Capacity, Registrations & Partnerships
- Shalvis Specialties commissioned: Commercial production began from the first block of the 100% subsidiary, which management says will fuel future growth.
- Japanese contract secured: A 3-year agreement to supply an intermediate to a prominent Japanese company; supply has started, and the Japanese company has visited the Shalvis site, raising hopes for more products.
- Registration pipeline advancing: Three advanced herbicide technicals received EU technical equivalence certification; registrations also secured in the UK, Canada and the US; three more products planned for the Australian market, with over 12 products in the pipeline with India's CIB authority.
- Capacity and land expansion: Installed technical and intermediates capacity increased to 24,200 metric tons; land acquired adjacent to the Sandila plant for further expansion.
- New asset-light subsidiary: Amona Specialities incorporated to operate under an asset-light business model.
- Capex plan: ₹50 crores for IPL and ₹60 crores for Shalvis Specialties in FY25, totaling ₹110 crores, funded entirely through internal accruals with no term loans.
Jain: "We are excited to announce the commissioning of our commercial production from first block of our 100% subsidiary, Shalvis Specialties, which will further fuel our future growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line growth | 15% to 20% revenue growth | FY25 and FY26 |
| Q1 FY25 revenue | Around ₹201 crores, at least 20% above Q4 FY24 | Q1 FY25 |
| Q1 FY25 vs Q1 FY24 | Q1 FY25 better than Q1 of last year | Q1 FY25 |
| FY23 revenue crossover | Definitely cross FY23 revenue | FY26 |
| FY23 volume recovery | Reach near FY23 volume, but not cross it | FY25 |
| Capex | ₹110 crores (₹50 cr IPL + ₹60 cr Shalvis), funded via internal accruals, no term loans | FY25 |
| Concrete EBITDA margin guidance | Will provide after 1-2 more quarters | 1-2 quarters from now |
| Demand stabilization | Another 1-2 quarters before stabilization | 1-2 quarters |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹127 cr, down 37% YoY from ₹200 cr in Q4 FY23 |
| Domestic revenue | ₹88 cr |
| Export revenue | ₹38 cr, down 65% YoY from ₹109 cr in Q4 FY23 |
| Full-year EBITDA margin | 15%, vs 24% in FY23 |
| Full-year PAT margin | 9% |
| Volume decline | 34% YoY, price decline 4% (per an analyst's math) |
| Cash and cash equivalents | ₹132 cr at quarter-end |
| FY25 capex plan | ₹110 cr, ₹50 cr for IPL and ₹60 cr for Shalvis Specialties |
| Installed capacity | 24,200 metric tons for technicals and intermediates |
| Export order book | ~₹100 cr |
| Key product price decline | 10% to 12% for Prosulfocarb, Captan, Folpet |
| Job work charges | ₹6 cr in Q4, shifted raw material cost to other expenses |
| FY25 revenue growth guidance | 15% to 20% over FY24 |
| Industry projected CAGR FY25-FY28 | ~9%, industry size to reach USD 14.5 bn by FY28 |